T0	Participants 63 91	progressive IgA nephropathy.
T1	Participants 145 217	38 patients with progressive IgA nephropathy and controlled hypertension
T2	Participants 868 940	Proteinuria, present in all patients at the time of entry into the trial
T3	Participants 1880 1940	Patients selected for moderately progressive IgA nephropathy